Walleye Capital
CRNX icon

Walleye Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Walleye Capital’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-34,500
Closed -$1.55M – 5385
2024
Q2 		$1.55M Buy
34,500
+33,800
+4,829% +$1.56M ﹤0.01% 2365
2024
Q1 		$32.8K Buy
+700
New +$27.4K ﹤0.01% 4799
2023
Q4 		– Sell
-700
Closed -$20.8K – 5022
2023
Q3 		$20.8K Buy
+700
New +$14.4K ﹤0.01% 4381

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Walleye Capital's CRNX Position: Q1 2026 in Review

Walleye Capital increased its Crinetics Pharmaceuticals (CRNX) stake by 671% in Q1 2026, buying an estimated $1.48M and bringing the position to 38,042 shares worth $1.38M. The position accounts for 0.01% of the portfolio, ranked #1782.

Walleye Capital first reported a position in CRNX in Q4 2020 and has held it in 18 quarters since. The position peaked at $14.1M in Q2 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Walleye Capital held 38,042 shares of Crinetics Pharmaceuticals worth $1.38M as of Q1 2026.
  • Walleye Capital bought 33,111 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $1.48M.
  • Crinetics Pharmaceuticals made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1782 holding.
  • Walleye Capital first reported a position in Crinetics Pharmaceuticals in Q4 2020 and has held it in 18 quarters since.
  • Walleye Capital's Crinetics Pharmaceuticals position peaked at $14.1M in Q2 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.